Eli Lilly and Company logo

Eli Lilly and Company (LLY)

Market Closed
16 Oct, 08:00 PM
NYSE NYSE
$
1,257. 03
+5.42
+0.433%
$
1.11T Market Cap
104.2 P/E Ratio
0.05% Div Yield
2.41M Volume
6.64 Eps
$ 1,251.61
Previous Close
Add Transaction
Day Range
1,251.25 1,274.56
Year Range
783.85 1,292.65
Want to track LLY and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Eli Lilly in negotiations with Trump administration for the next pharma deal

Eli Lilly in negotiations with Trump administration for the next pharma deal

CNBC's Eamon Javers reports on news regarding the White House.

Youtube | 1 year ago
Is Lilly (LLY) a Buy as Wall Street Analysts Look Optimistic?

Is Lilly (LLY) a Buy as Wall Street Analysts Look Optimistic?

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Zacks | 1 year ago
Eli Lilly and Company (LLY) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript

Eli Lilly and Company (LLY) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript

Eli Lilly and Company (NYSE:LLY ) Bernstein 2nd Annual Global Healthcare Conference September 25, 2025 8:00 AM EDT Company Participants Lucas Montarce - Executive VP & CFO Mike Czapar - Director of Investor Relations Conference Call Participants Courtney Breen - Sanford C. Bernstein & Co., LLC.

Seekingalpha | 1 year ago
Eli Lilly's boss calls UK the 'worst' European country for drug prices

Eli Lilly's boss calls UK the 'worst' European country for drug prices

Eli Lilly Chief Executive Dave Ricks said Britain was "probably the worst country in Europe" for drug prices in an interview with the Financial Times, intensifying pressure on the government to improve market conditions for drugmakers.

Reuters | 1 year ago
Eli Lilly to Build $6.5 Billion Ingredient-Manufacturing Facility in Texas

Eli Lilly to Build $6.5 Billion Ingredient-Manufacturing Facility in Texas

The planned site, which will be used to manufacture the company's first oral weight-loss drug, is expected to be operational within five years.

Wsj | 1 year ago
LLY's Orforglipron Tops NVO's Oral Pill in Diabetes Study: What's Next?

LLY's Orforglipron Tops NVO's Oral Pill in Diabetes Study: What's Next?

Eli Lilly's orforglipron beat NVO's Rybelsus in a 52-week diabetes study, showing stronger A1C and weight loss benefits.

Zacks | 1 year ago
Lilly's Mounjaro helps improve blood sugar control in children in late-stage trial

Lilly's Mounjaro helps improve blood sugar control in children in late-stage trial

Eli Lilly's Mounjaro helped children and adolescents aged 10 to 17 years with type 2 diabetes manage their blood sugar better and lose weight, according to trial results presented at a medical meeting on Wednesday.

Reuters | 1 year ago
LLY's $5B Virginia Plant Plan: Will U.S. Manufacturing Shift Pay Off?

LLY's $5B Virginia Plant Plan: Will U.S. Manufacturing Shift Pay Off?

Eli Lilly will invest $5B in a new Virginia plant to make cancer drugs, creating 650 jobs amid Trump's tariff push.

Zacks | 1 year ago
Why the Market Dipped But Eli Lilly (LLY) Gained Today

Why the Market Dipped But Eli Lilly (LLY) Gained Today

Eli Lilly (LLY) concluded the recent trading session at $763.57, signifying a +2.06% move from its prior day's close.

Zacks | 1 year ago
Lilly CEO: U.K. has gone from biopharma leader to laggard

Lilly CEO: U.K. has gone from biopharma leader to laggard

Lilly CEO Dave Ricks explains why pricing dynamics in the U.K. make it a very unattractive place for Lilly to invest.

Youtube | 1 year ago
Eli Lilly to build $5 billion Virginia facility to boost production of targeted cancer drugs, other treatments

Eli Lilly to build $5 billion Virginia facility to boost production of targeted cancer drugs, other treatments

Eli Lilly on Tuesday said it will spend $5 billion to build a manufacturing facility in Goochland County, Virginia, to boost production capacity for targeted cancer drugs and other treatments. The plant is the company's first of four planned U.S. manufacturing sites, which will begin making medicines within five years.

Cnbc | 1 year ago
Oxford Industries says new Lilly Pulitzer offerings are winning over shoppers, but its Tommy Bahama line is lagging

Oxford Industries says new Lilly Pulitzer offerings are winning over shoppers, but its Tommy Bahama line is lagging

Resort-style clothing maker Oxford Industries Inc. on Wednesday offered up mixed second-quarter results and third-quarter expectations, and said that while new Lilly Pulitzer offerings were attracting shoppers, its Tommy Bahama line wasn't.

Marketwatch | 1 year ago
Loading...
Load More